Sutro Biopharma

Sutro's XpressCF+ platform is a cell-free protein synthesis system that produces proteins without living cells. It allows site-specific conjugation of cytotoxic payloads to antibodies, creating highly uniform antibody-drug conjugates. This precision is difficult to achieve with traditional mammalian cell culture, per the firm's official communications.

ELAHERE (mirvetuximab soravtansine) is an ADC targeting folate receptor alpha in platinum-resistant ovarian cancer. The drug was developed by ImmunoGen using Sutro's technology and received FDA accelerated approval in November 2022. It became the first drug approved based on a Sutro-enabled construct.

Sutro Biopharma is a clinical-stage biopharmaceutical company, not a family office or investment manager. It generates data through internal drug development, funded by public equity and pharmaceutical partnerships. Institutional allocators encounter it as a Nasdaq-listed equity, not as a capital manager.

Sutro has disclosed collaboration agreements with Merck, Celgene (now Bristol Myers Squibb), and Astellas. These deals involve developing bispecific ADCs and cytokine-based immunotherapies using Sutro's platform, generating upfront and milestone payments that partially fund internal pipeline development.

Traditional ADC manufacturing relies on mammalian Chinese hamster ovary cell lines, which can introduce heterogeneity in conjugation sites. Sutro's cell-free system produces proteins in vitro, enabling pre-defined conjugation at engineered non-natural amino acids. This results in drug-to-antibody ratios that are exactly uniform, not averaged.